拉丁美洲系统性红斑狼疮治疗首部临床实践指南:拉丁美洲狼疮研究组(GLADEL)-泛美风湿病学会联盟(PANLAR)
该指南由风湿病学专家与方法学家组成的两个独立团队制定,针对拉丁美洲系统性红斑狼疮(SLE)患者常见临床问题,采用GRADE方法形成推荐。指南涵盖九个器官/系统章节及总体治疗路径,重点考察糖皮质激素、抗疟药、免疫抑制剂、血浆置换、贝利尤单抗、利妥昔单抗、阿巴西普、低剂量阿司匹林和抗凝药的作用,并强调区域实施中的民族与社会经济因素。
要点
- 指南采用GRADE方法制定,涵盖九个器官/系统章节及总体治疗路径。
- 针对拉丁美洲SLE患者,评估了糖皮质激素、抗疟药、免疫抑制剂等主要治疗选择的获益与危害。
- 推荐形成中考虑了证据确定性、价值观偏好、可行性、可接受性及公平性等区域实施问题。
核心结论
- 已制定针对拉丁美洲狼疮患者的临床实践指南,可用于类似环境。
研究设计与样本
- 由风湿病学 lupus 管理经验专家与方法学家两个独立团队制定,2016年4月在巴拿马城初步选定额临床问题,采用GRADE方法总结最佳证据,2016年11月在华盛顿特区面对面讨论所有初步发现。
主要发现
- 指南呈现九个器官/系统章节的主要发现,并增加总体治疗路径。
- 各章节总结糖皮质激素、抗疟药、免疫抑制剂、治疗性血浆置换、贝利尤单抗、利妥昔单抗、阿巴西普、低剂量阿司匹林和抗凝药的作用。
- 推荐形成中考虑获益与危害、证据确定性、价值观与偏好、可行性、可接受性及公平性,特别关注民族与社会经济方面。
关键数值与推荐
- 指南针对肌肉骨骼、皮肤黏膜、肾脏、心脏、肺、神经精神、血液系统表现及抗磷脂综合征考察最佳药物选择。
临床怎么用
- 指南可供拉丁美洲SLE患者使用,并可用于类似环境。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings.
引用
- Pons-Estel BA, Bonfa E, Soriano ER, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018. PMID: 30045853. doi:10.1136/annrheumdis-2018-213512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。